Literature DB >> 23084689

Malignant ovarian Sertoli-Leydig cell tumor localized with selective ovarian vein sampling.

Caitlin Dunne1, Jon C Havelock.   

Abstract

Sertoli-Leydig cell tumors (SLCT) are rare, comprising less than 0.5% of ovarian neoplasms. They are most often diagnosed in premenopausal women and may produce androgens, resulting in hirsuitism, voice deepening, frontal balding, terminal hair growth, and clitoromegaly. SLCT are malignant in 15%-20% of cases. We discuss a 25-year-old patient with persistent hyperandrogenemia. Noninvasive imaging cannot conclusively differentiate between SCLT and other diagnoses such as polycystic ovary syndrome, ovarian hyperthecosis, idiopathic hyperandrogenism, idiopathic hirsuitism, and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Selective ovarian vein sampling revealed a 15-fold greater testosterone production from the right ovary compared with the left, which guided appropriate surgical management.
Copyright © 2012 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23084689     DOI: 10.1016/j.jmig.2012.08.006

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  3 in total

1.  MENOPAUSAL ANDROGEN EXCESS - ASSOCIATED CARDIO-METABOLIC RISK: CLUES FOR OVARIAN LEYDIG CELL TUMOUR (CASE REPORT AND MINI-REVIEW OF LITERATURE).

Authors:  A A Gheorghisan-Galateanu; D Terzea; A Valea; M Carsote
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jul-Sep       Impact factor: 0.877

Review 2.  The utility of adrenal and ovarian venous sampling in a progesterone-producing adrenal tumor and review of the literature.

Authors:  Lian Duan; Yingying Yang; Yu Gu; Xiaobo Zhang; Quanzong Mao; Boju Pan; Chengyan Deng; Hui Pan; Huijuan Zhu
Journal:  Endocrine       Date:  2019-08-27       Impact factor: 3.633

Review 3.  Recent Advances in the Clinical Application of Adrenal Vein Sampling.

Authors:  Shan Zhong; Tianyue Zhang; Minzhi He; Hanxiao Yu; Zhenjie Liu; Zhongyi Li; Xiaoxiao Song; Xiaohong Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-09       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.